These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38448817)

  • 21. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
    Hu Z; Huang S; Wu Y; Liu Y; Liu X; Su D; Tao Y; Fu P; Zhang X; Peng Z; Zhang S; Yang Y
    Kidney Int; 2014 Feb; 85(2):416-24. PubMed ID: 24025644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J
    Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein Glomerulopathy, First Case Report from Canada.
    Ting JA; McRae SA; Schwartz D; Barbour SJ; Riazy M
    Int J Nephrol Renovasc Dis; 2022; 15():207-214. PubMed ID: 35761986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Identification of a mutation in exon 4 of apolipoprotein E gene in a family affected with lipoprotein glomerulopathy].
    Han HL; Lin S; Sun LS; Zhang P; Zhai DP
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):141-4. PubMed ID: 22487820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein e mutation and double filtration plasmapheresis therapy on a new Chinese patient with lipoprotein glomerulopathy.
    Li W; Wang Y; Han Z; Luo C; Zhang C; Xiong J
    Kidney Blood Press Res; 2014; 39(4):330-9. PubMed ID: 25300642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein glomerulopathy in China.
    Chen Y
    Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
    Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Li LS
    J Nephrol; 2008; 21(1):110-7. PubMed ID: 18264944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
    Hamatani H; Hiromura K; Kobatake K; Yoshida H; Kobayashi S; Yoneda N; Kayakabe K; Matsumoto T; Kuroiwa T; Ueki K; Nojima Y
    Clin Exp Nephrol; 2010 Dec; 14(6):619-24. PubMed ID: 20842518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.
    Li MS; Li Y; Liu Y; Zhou XJ; Zhang H
    Front Med (Lausanne); 2022; 9():905007. PubMed ID: 35602473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
    Saito T; Matsunaga A; Oikawa S
    Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension.
    Wu Y; Chen X; Yang Y; Wang B; Liu X; Tao Y; Fu P; Hu Z
    BMC Nephrol; 2013 Feb; 14():53. PubMed ID: 23448537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein E-related glomerular disorders.
    Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
    Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Discovery of a Chinese Tibetan patient with lipoprotein glomerulopathy due to APOE Osaka/Kurashiki variant].
    Yang Z; Wu H; Hu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):166-169. PubMed ID: 32034747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topics in lipoprotein glomerulopathy: an overview.
    Saito T; Matsunaga A; Ito K; Nakashima H
    Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
    Ishigaki Y; Oikawa S; Suzuki T; Usui S; Magoori K; Kim DH; Suzuki H; Sasaki J; Sasano H; Okazaki M; Toyota T; Saito T; Yamamoto TT
    J Biol Chem; 2000 Oct; 275(40):31269-73. PubMed ID: 10903326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.
    Cambruzzi E; Pêgas KL
    J Bras Nefrol; 2019; 41(3):393-399. PubMed ID: 30421781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child.
    Pêgas KL; Rohde R; Garcia CD; Bittencourt Vde B; Keitel E; Poloni JA; Cambruzzi E
    J Bras Nefrol; 2014; 36(1):93-5. PubMed ID: 24676620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.
    Takasaki S; Matsunaga A; Joh K; Saito T
    CEN Case Rep; 2018 May; 7(1):127-131. PubMed ID: 29356944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
    Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
    Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first case of lipoprotein glomerulopathy complicated with collagen type III glomerulopathy and literature review.
    Liu H; Luo C; Li Z; Zhang C; Xiong J
    J Nephrol; 2023 Apr; 36(3):663-667. PubMed ID: 36370330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.